Maiwald
Lawyers at Maiwald and Sterne Kessler analyse how patents with claims directed to medical treatments are handled in the US and in Europe
Sponsored
Sponsored
-
Sponsored by Maiwald Intellectual PropertyMarco Stief of Maiwald explains a ruling by the Düsseldorf Regional Court in the matter NuCana v Gilead that establishes the subsidiarity of the objection of disproportionality with regard to a compulsory licensing action -
Sponsored by Maiwald Intellectual PropertySusanna Heurung of Maiwald examines a decision by the European Court of Justice concerning the ending of a period of ‘acquiescence’ in a trademark case and what it means for potential plaintiffs
-
Sponsored by Maiwald Intellectual PropertyOwners of German trademarks who rely on their use in Switzerland to protect their mark must change their strategy immediately, as Susanna Heurung of Maiwald explains
-
Sponsored by Maiwald Intellectual PropertyHeike Röder-Hitschke of Maiwald discusses a significant European Court of Justice (CJEU) ruling, and how it will affect future practice in preliminary injunction proceedings
-
Sponsored by Maiwald Intellectual PropertySimon Lud of Maiwald explains how a German court judgment is advantageous for patent applications in the fields of artificial intelligence and quantum computing
-
Sponsored by Maiwald Intellectual PropertyMatthias Hoffmann of Maiwald discusses the uncertainty over the transfer of priority rights and the joint applicants approach at the EPO
